Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Mylotarg · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Mylotarg (gemtuzumab ozogamicin) Injection | DRUG | - |
Inclusion Criteria * Patients with CD33+ AML who have experienced relapse after autologous or allogeneic HSCT. Flow cytometry, performed at the study site, must demonstrate that the patient has AML that is CD33 positive, based on local laboratory criteria (Patients with history of MDS pretransplant...
Mylotarg is used for Acute Myelogenous Leukemia (AML). It is being studied as a treatment for patients with this condition, specifically in the context of post-stem cell transplant therapy. The drug is currently in clinical development for this indication.
Mylotarg targets CD33, an antigen expressed on leukemic blasts in most patients with Acute Myelogenous Leukemia. By binding to CD33, the drug delivers a cytotoxic agent to the cancer cells. This mechanism is the basis for its use in AML treatment.
Mylotarg is developed by Pfizer, Inc. (NYSE: PFE). The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with Acute Myelogenous Leukemia.
Mylotarg is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA for the treatment of Acute Myelogenous Leukemia. The drug is still undergoing clinical trials to assess its potential.
Mylotarg has one completed clinical trial, NCT00044733, titled 'Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant'. This Phase 2 trial enrolled 38 participants in the United States and was not randomized or blinded.
Yes, Mylotarg is the brand name for gemtuzumab ozogamicin. The clinical trial NCT00044733 uses the generic name gemtuzumab ozogamicin to refer to the drug. Both names refer to the same investigational therapy for Acute Myelogenous Leukemia.